- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma
TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.
Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.
"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's resear《环亚游戏》ch, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."
Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.
"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."
Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.
About Ripple Therapeutics
Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors.
Piper Sandler acted as the exclusive financial advisor to Ripple.
For further information:
Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com, 416-951-7988
SOURCE: Ripple Therapeutics
【环球时报综合报道】据路透社10日报道 ❎，国际数据公司（IDC）9日发布的报告显示，由于需求疲软、库 ⌚存过剩和宏观经济环境恶化，2023年第一季度全球个人电脑（PC）出货量仅为5690万台，同期下降29%，其中苹果公司受到 ♌的打击最大 ♎，环亚游戏该公司第一季度出货量同比降幅达40.5%。
本报告仅供中国石油流通协会（协会）和山东隆众信息技术有 ♍限公司（隆众资讯）的客户使用，未经协会和隆众资讯授权许可，严 ♒禁环亚游戏任何形式的转载、翻版、复制或传播。如引用、刊发，须注明出处 ⌛来自协会和隆众资讯，且不得对本报告进行任何有悖原意的引用及修 改。
本报记者 孟湄 【编辑:周建烈 】
